Skip to content

Study · Randomized controlled trial · n = 129 · 2005

8 results

Use of a GnRH antagonist in controlled ovarian hyperstimulation for assisted conception in women with polycystic ovary disease: a randomized, prospective, pilot study.

Bahçeci M, Ulug U, Ben-Shlomo I, Erden HF, Akman MA

The Journal of reproductive medicine1 Feb 2005Cited by 41 (Europe PMC)

PMID15755044 (opens in a new tab)PepBankPUB-15755044
Publisher pageAsk about this study
Jump to 8 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study8

8 results from studies that gave the peptide. 8 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In women with PCOD, gonadotropin ampule consumption did not differ significantly between leuprolide and antagonist protocols.

    In plain wordsWomen with PCOD used similar gonadotropin amounts with leuprolide and antagonist protocols.

    Peptide
    Leuprolide
    Outcome
    No significant changeGonadotropin ampules per cycle
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    There was no significant difference between the antagonist and agonist arms in the number of gonadotropin ampules consumed per cycle.
    1 context sentence
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In women with PCOD, ovarian stimulation lasted longer with leuprolide than with the antagonist.

    In plain wordsOvarian stimulation lasted longer with leuprolide than with the antagonist in women with PCOD.

    Peptide
    Leuprolide
    Outcome
    IncreaseOvarian stimulation duration
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    However, in the antagonist arm a shorter duration of ovarian stimulation was recorded as compared to the agonist arm.
    1 context sentence
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In women with PCOD, similar numbers of oocytes were retrieved with leuprolide and antagonist protocols.

    In plain wordsWomen with PCOD had similar numbers of eggs retrieved with leuprolide and antagonist protocols.

    Peptide
    Leuprolide
    Outcome
    Direction not reportedOocytes retrieved
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although similar numbers of oocytes was retrieved from both groups of patients, the quality of the oocytes, as measured by metaphase 2/total oocyte ratio, was lower in the antagonist arm as compared to the agonist arm.
    1 context sentence
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  4. 04HumanRandomized controlled trialEfficacy outcome

    In women with PCOD, the metaphase 2/total oocyte ratio was higher with leuprolide than with the antagonist.

    In plain wordsEgg quality, measured by the metaphase 2 ratio, was higher with leuprolide than with the antagonist in women with PCOD.

    Peptide
    Leuprolide
    Outcome
    IncreaseMetaphase 2/total oocyte ratio
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Although similar numbers of oocytes was retrieved from both groups of patients, the quality of the oocytes, as measured by metaphase 2/total oocyte ratio, was lower in the antagonist arm as compared to the agonist arm.
    1 context sentence
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  5. 05HumanRandomized controlled trialEfficacy outcome

    In women with PCOD, pregnancy rates were 58.5% with leuprolide and 57.6% with the antagonist, without a significant difference.

    In plain wordsPregnancy rates did not differ significantly between leuprolide and the antagonist in women with PCOD.

    Peptide
    Leuprolide
    Outcome
    No significant changePregnancy rate
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Pregnancy rate
    58.5%
    leuprolide
    Pregnancy rate
    57.6%
    antagonist
    P
    > 0.05
    comparison

    Source sentences

    Summary
    Pregnancy rates were 57.6% and 58.5% in the antagonist and agonist arms, respectively (p > 0.05).
    1 context sentence
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  6. 06HumanRandomized controlled trialEfficacy outcome

    In women with PCOD, implantation rates did not differ between leuprolide and antagonist protocols, at 34.6% and 34.0%, respectively.

    In plain wordsImplantation rates were similar with leuprolide and the antagonist in women with PCOD.

    Peptide
    Leuprolide
    Outcome
    No significant changeImplantation rate
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Implantation rate
    34.6%
    leuprolide
    Implantation rate
    34%
    antagonist

    Source sentences

    Summary
    Implantation rates were not different (34.0% and 34.6%, respectively).
    2 context sentences
    Summary · context
    Pregnancy rates were 57.6% and 58.5% in the antagonist and agonist arms, respectively (p > 0.05).
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  7. 07HumanRandomized controlled trialSafety outcome

    In women with PCOD, ovarian hyperstimulation syndrome did not differ between leuprolide and antagonist protocols, at 7.1% and 5%, respectively.

    In plain wordsOvarian hyperstimulation syndrome rates were similar with leuprolide and the antagonist in women with PCOD.

    Peptide
    Leuprolide
    Outcome
    No significant changeOvarian hyperstimulation syndrome
    Study

    n = 129

    Comparator
    GnRH antagonist
    Outcome group
    Adverse events · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Ovarian hyperstimulation syndrome
    7.1%
    leuprolide
    Ovarian hyperstimulation syndrome
    5%
    antagonist

    Source sentences

    Summary
    The frequency of ovarian hyperstimulation syndrome also did not differ between the treatment groups (5% and 7.1%, respectively).
    2 context sentences
    Summary · context
    Pregnancy rates were 57.6% and 58.5% in the antagonist and agonist arms, respectively (p > 0.05).
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.
  8. 08HumanNon-randomized trialEfficacy outcome

    In women with PCOD receiving leuprolide for assisted conception, no cycles were cancelled because of a premature LH surge.

    In plain wordsNo leuprolide cycles were cancelled because of an early LH surge in women with PCOD.

    Peptide
    Leuprolide
    Outcome
    Not applicableCycle cancellation due to premature LH surge
    Study

    n = 70

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Source sentences

    Summary
    None of the cycles were cancelled due to a premature LH surge.
    1 context sentence
    Summary · context
    A total of 129 patients with PCOD were randomly allocated to undergo COH with a GnRH antagonist (59 patients) and GnRH agonist (leuprolide acetate) (70 patients) to prevent a premature luteinizing hormone (LH) surge.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.